BRYCE RICHARD PAUL 4
4 · PUMA BIOTECHNOLOGY, INC. · Filed Apr 6, 2021
Insider Transaction Report
Form 4
BRYCE RICHARD PAUL
SR VP, CLINICAL RESEARCH & DEV
Transactions
- Sale
COMMON STOCK
2021-04-05$9.80/sh−426$4,176→ 121,662 total
Footnotes (1)
- [F1]The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units.